pharmaphorum

MARCH 15, 2021

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies. This is made possible using ‘Advanced Host Immune Response Technologies’. The pace of work in the industry reached almost ludicrous speeds.

Immune Response 71

Immune Response Vaccination Vaccine Protein 71

Pharma Mirror

OCTOBER 16, 2023

The first mRNA drug (BNT162b2 vaccine) was granted emergency use authorization by the FDA in December 2020 and approved for marketing in August 2021.

Drugs 130

Drugs Immune Response Protein Vaccination 130

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. All participants in the phase 2 trials (40 participants) produced antibodies against the SARS-CoV-2 spike protein.

Immune Response 107

Immune Response Vaccination Vaccine Antibody 107

Pharmaceutical Technology

NOVEMBER 11, 2022

The European Commission (EC) has granted approval for Sanofi and GSK ’s monovalent, recombinant-protein-based, adjuvanted Covid-19 vaccine, VidPrevtyn Beta, as a booster in adults aged 18 years and above. It is indicated as a booster in people of this age group who were earlier inoculated with a Covid-19 vaccine.

Vaccination 246

Vaccination Vaccine Immune Response Protein 246

Scienmag

MARCH 10, 2022

Close interactions with infectious disease set both University of California, Santa Cruz graduate student Ana Nuñez Castrejon and Associate Professor of Biomolecular Engineering Rebecca DuBois on the path of studying Respiratory syncytial virus (RSV), a common and sometimes dangerous respiratory disease for which there is not currently a vaccine.

Immune Response 77

Immune Response Vaccination Vaccine Protein 77

Pharmaceutical Technology

MAY 29, 2023

A protein-based vaccine, Nuvaxovid has been recommended for MA for use as a primary series in individuals of the age 12 years and above and as a booster in those aged 18 years and older to prevent Covid-19. NVX-CoV2373 is developed by making copies of the surface spike protein of the SARS-CoV-2 virus that causes Covid.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130

Medical Xpress

FEBRUARY 21, 2023

PCB2DG, a polyphenol with anti-inflammatory properties, works by targeting and directly interacting with the major glutamine transporter protein, alanine serine cysteine transporter 2 (ASCT2), to inhibit the uptake of glutamine, an important amino acid found in the blood.

Immune Response 72

Immune Response Regulation Protein 72

Scienmag

MARCH 17, 2022

The study, published in the journal Molecular Neurobiology led by the University’s Dr Mayo Olajide, describes how the spike protein used by the coronavirus to enter human cells can have a similar effect on the brain’s immune cells as it does with the rest of the body Credit: University of Huddersfield The study, published in […].

Immune Response 82

Immune Response Scientist Protein 82

Pharmaceutical Technology

OCTOBER 25, 2022

A human monoclonal antibody, Imfinzi attaches to the PD-L1 protein and hinders the PD-L1 interaction with the PD-1 and CD80 proteins. Imjudo is also a human monoclonal antibody and hinders cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) activity.

FDA Approval 173

FDA Approval Antibody Protein Clinical Trials 173

The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV. “In Induction of innate immunity was investigated via specific cytokine markers.

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Scienmag

NOVEMBER 16, 2021

Despite great progress with SARS-CoV-2 vaccines, there is still a need to accelerate vaccination in low- and middle-income countries and a need for more effective vaccine strategies in older adults, who tend to have weaker immune responses to vaccination.

Protein 84

Protein Vaccination Vaccine Immune Response 84

The Pharma Data

MAY 17, 2021

The investigational COVID-19 vaccine uses the same recombinant protein-based technology as one of Sanofi’s seasonal flu vaccines, along with GSK’s established pandemic adjuvant technology. The interim results from the phase 2 trial on the vaccine, published today, on the contrary, showed a “ strong neutralizing antibody response” ?

Immune Response 52

Immune Response Vaccination Vaccine Antibody 52

Pharmaceutical Technology

APRIL 5, 2023

Initially, the company will use its reverse immunology technology to search the database for antibodies from patients showing strong immune responses. This is an important leap forward to better understand individualised protein-protein interactions on cancer cells, moving us toward delivering on the promise of personalised medicine.”

Drugs 130

Drugs Bioinformatics Antibody Development 130

BioTech 365

AUGUST 19, 2021

Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong … Continue reading →

Immune Response 40

Immune Response Vaccination Vaccine Protein 40

Medical Xpress

MAY 10, 2023

SLFN 12 shuts down viral protein production and helps virus-infected cells to escape from anti-HIV therapy and immune responses. These findings pave the way for improving therapeutic strategies that aim to cure HIV infections.

Immune Response 111

Immune Response Protein Research Production 111

Pharmaceutical Technology

AUGUST 18, 2022

New Zealand’s Medsafe has granted expanded provisional approval for Novavax ’s protein-based Covid-19 vaccine Nuvaxovid (NVX-CoV2373) as a heterologous and homologous booster dose in adults aged 18 years and above. The booster vaccine is indicated for active immunisation for the prevention of Covid-19 in people of this age group.

Immune Response 130

Immune Response Vaccination Vaccine Clinical Trials 130

Pharmaceutical Technology

MARCH 31, 2023

Bimervax is a recombinant protein subunit vaccine, marketed by the Girona, Spain-based Hipra. Eligibility for the UK’s National Health Services (NHS) booster programmes in England is restricted to those ages 75 years and above or individuals with weakened immune systems.

Vaccination 277

Vaccination Vaccine Antibody Clinical Trials 277

Pharmaceutical Technology

APRIL 11, 2023

The vaccine, which generates the SARS-CoV-2 viral spike protein on administration, induces the immune system’s cellular and humoral arm-mediated immune response. The company began supplying the first consignment to the government of India in February 2022.

FDA Approval 130

FDA Approval Drugs Immune Response Vaccination 130

Pharmaceutical Technology

NOVEMBER 20, 2022

Health Canada has granted expanded authorisation for Novavax ’s Covid-19 vaccine (Recombinant protein, Adjuvanted) [Nuvaxovid; NVX-CoV2373] as a homologous booster for usage in adults aged 18 and above. Novavax president and CEO Stanley Erck said: “Canadians now have access to our protein-based Nuvaxovid Covid-19 vaccine as an adult booster.

Vaccination 147

Vaccination Vaccine Clinical Trials Clinical Trials 147

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials.

Vaccination 147

Vaccination Vaccine Clinical Trials Clinical Trials 147

Pharmaceutical Technology

FEBRUARY 15, 2023

Cancer monoclonal antibody therapy is a key innovation area in immuno-oncology Monoclonal antibodies are synthetic proteins that target cancer cells directly (targeted therapies) or help improve the immune system’s response to cancer cells (passive immunotherapy).

Antibody 261

Antibody Immune Response Protein Research 261

Medical Xpress

APRIL 17, 2023

The findings, published in Science Translational Medicine, suggests that breaches in damaged gums allow bacteria in the mouth to seep into the bloodstream, activating an immune response that ultimately pivots to target the body's own proteins and causes arthritis flareups.

Immune Response 98

Immune Response Bacteria Protein Medicine 98

BioSpace

NOVEMBER 7, 2022

Researchers from the University of Washington have developed an investigational vaccine that can safely elicit an immune response against the HER2 protein, a key marker in breast cancer.

Vaccination 98

Vaccination Vaccine Immune Response Protein 98

Medical Xpress

FEBRUARY 14, 2023

This limits glucose availability for immune cells and therefore dampens the body's anti-cancer immune response. Tumor cells typically alter their energy metabolism and increase glucose uptake to support their rapid division and spread.

Immune Response 72

Immune Response Protein Scientist 72

Scienmag

NOVEMBER 10, 2020

Mid-range level of immune protein associated with lowest risk Philadelphia, November 10, 2020 – The causes of autism spectrum disorder (ASD) – including genetic and environmental factors – are not entirely understood.

Immune Response 70

Immune Response Genetics Protein Medicine 70

Scienmag

OCTOBER 14, 2020

Treatment with a peptide that mimics the naturally occurring protein GIV prevents immune overreaction, supports a mechanism critical for survival in mouse models of sepsis and colitis Credit: UC San Diego Health Sciences The immune response to infections is a delicate balance.

Protein 67

Protein Immune Response Bacteria Allergies 67

Pharmaceutical Technology

MAY 17, 2023

It has been designed for controlling the complement factor C5a, which is a protein that plays an important and harmful role in the immune response of the body. The treatment is an investigational first-in-class monoclonal anti-human complement factor C5a antibody.

Manufacturing 130

Manufacturing Immune Response Antibody Drugs 130

pharmaphorum

JULY 6, 2021

While these types of tests are important, they don’t tell the whole story, as they can’t provide information on whether an individual has built an immune response to COVID-19, either through vaccination or through a previous infection. This is where antibody tests come in. The Importance of Antibody Certificates.

Antibody 111

Antibody Immune Response Protein Vaccination 111

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Vaccination 97

Vaccination Vaccine Protein Trials 97

Pharmaceutical Technology

FEBRUARY 15, 2023

The structural proteins include the capsid, pre-membrane/membrane proteins and envelope (E) proteins. The non-structural proteins NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 are involved in viral RNA replication and dampening of the host innate immune response.

Vaccination 130

Vaccination Vaccine Protein Antibody 130

Drug Discovery World

OCTOBER 5, 2023

“In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability. The funding follows a successful collaboration with NVIDIA earlier this year, in which the companies developed an AI model that can be used to design therapeutic proteins.

Drugs 52

Drugs Immune Response Protein Gene 52

Scienmag

OCTOBER 6, 2020

— Researchers at Penn State College of Medicine now better understand the role of a protein, interleukin-21 (IL-21), in the immune system response to infections in the nervous system. HERSHEY, Pa.

Protein 40

Protein Immune Response Medicine Research 40

pharmaphorum

JANUARY 5, 2022

A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial.

Vaccination 126

Vaccination Vaccine Protein Immune Response 126

Medical Xpress

DECEMBER 16, 2022

They have just discovered that a key immune alarm protein previously believed to calm down the immune response actually does the opposite. Scientists from Trinity College Dublin have made an important breakthrough in understanding how inflammation is regulated.

Immune Response 81

Immune Response Protein Scientist Regulation 81

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion CEO Per Norlén said: “We believe that ExpreS 2 ion´s superb platforms for the production of complex proteins are a great match with our AI platform for target discovery and our novel technologies for inducing strong immune responses.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

APRIL 18, 2023

Innovation S-curve for the pharmaceutical industry HIV peptides is a key innovation area in pharmaceuticals HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Antibody 147

BioPharma Reporter

DECEMBER 11, 2020

Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105